Transaction details
On March 30, 2026, Martine Rothblatt, who serves as Chairperson and CEO of United Therapeutics (NASDAQ: UTHR), completed a sale of company stock totaling $5.6 million. The disposition was carried out under an established 10b5-1 trading plan and comprised 6,737 shares of common stock sold at prices between $581.74 and $602.7167 per share.
Also on March 30, Rothblatt exercised stock options to acquire 9,500 shares of United Therapeutics common stock at an exercise price of $146.03 per share, resulting in an aggregate acquisition value of $1,387,285.
About the 10b5-1 plan and ownership
The 10b5-1 plan cited in the filings was adopted on November 7, 2025. Under its terms, it permits the exercise of up to 1,734,410 stock options that expire on March 17, 2027, and the plan will remain effective until the earlier of that exercise limit or December 31, 2026. Following the March 30 transactions, Rothblatt is recorded as directly owning 40,513 shares of United Therapeutics common stock. She also retains indirect ownership through a number of trusts.
Analyst reactions tied to clinical data
The stock transactions occurred against a backdrop of multiple analyst updates after United Therapeutics reported positive Phase 3 TETON-1 results for Tyvaso in idiopathic pulmonary fibrosis (IPF).
H.C. Wainwright raised its price target on United Therapeutics to $660 from $600 and kept a Buy rating, citing the TETON-1 data as a supportive factor for broader use of Tyvaso. BofA Securities increased its price target to $626 from $569 while maintaining a Neutral rating, describing the trial as a second confirmation of the drug’s efficacy in the IPF indication. Jefferies moved its price target materially higher to $733 from $668 and retained a Buy rating, noting an increased probability of success for the IPF indication based on the trial findings.
The TETON-1 study, which enrolled patients in the United States and Canada, was reported to have exceeded expectations from both investors and the covering firms. Jefferies additionally observed that these results compared favorably to the TETON-2 study conducted outside North America.
Context for investors
Investors seeking more detailed valuation and performance metrics on UTHR can consult the comprehensive Pro Research Report available for this and 1,400+ other U.S. equities on InvestingPro.
While the filings provide specific transaction amounts, option details and current direct ownership figures, they do not disclose any further trading intentions beyond the parameters of the disclosed 10b5-1 plan.